|Articles|November 8, 2019

WCG Acquires Waife & Associates, Inc.

WIRB-Copernicus Group's Clinical Services Division has announced the acquisition of Waife & Associates, Inc. With this acquisition, W&A's Founder Ronald S. Waife becomes WCG's Chief Management Consulting Officer.

To learn more about the acquisition, click here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
September 16th 2025
Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares
September 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial Design
September 16th 2025
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
September 15th 2025
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025

WCG Acquires Waife & Associates, Inc.

Newsletter

Related Articles

Trending on Applied Clinical Trials Online

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares